OBJECTIVE: To evaluate immunogenicity and safety of a polygeline-free tick-born encephalitis (TBE) vaccine in a clinical program. METHOD: A total of 3118 subjects aged 12-76 years were enrolled in three clinical trials. The clinical studies were conducted in 15 centers in three European countries. Evidence of neutralizing TBE antibodies was used as surrogate parameter for efficacy assessment. RESULTS: All subjects analyzed achieved levels of TBE antibodies postimmunization to fulfill the definition of seroconversion or a four-fold increase. The new TBE vaccine appeared to be well tolerated by subjects. Only very few febrile reactions, mainly 38.5 degrees C were reported. No serious or unexpected adverse events related to vaccination were reported. CONCLUSION: These successful results in terms of both immunogenicity and safety indicate that the TBE vaccination with this polygeline-free TBE vaccine can be used safely in adolescents and adults.
OBJECTIVE: To evaluate immunogenicity and safety of a polygeline-free tick-born encephalitis (TBE) vaccine in a clinical program. METHOD: A total of 3118 subjects aged 12-76 years were enrolled in three clinical trials. The clinical studies were conducted in 15 centers in three European countries. Evidence of neutralizing TBE antibodies was used as surrogate parameter for efficacy assessment. RESULTS: All subjects analyzed achieved levels of TBE antibodies postimmunization to fulfill the definition of seroconversion or a four-fold increase. The new TBE vaccine appeared to be well tolerated by subjects. Only very few febrile reactions, mainly 38.5 degrees C were reported. No serious or unexpected adverse events related to vaccination were reported. CONCLUSION: These successful results in terms of both immunogenicity and safety indicate that the TBE vaccination with this polygeline-free TBE vaccine can be used safely in adolescents and adults.
Authors: Michael M Lieberman; David E Clements; Steven Ogata; Gordon Wang; Gloria Corpuz; Teri Wong; Tim Martyak; Lynne Gilson; Beth-Ann Coller; Julia Leung; Douglas M Watts; Robert B Tesh; Marina Siirin; Amelia Travassos da Rosa; Tom Humphreys; Carolyn Weeks-Levy Journal: Vaccine Date: 2006-08-30 Impact factor: 3.641
Authors: Michael M Lieberman; Vivek R Nerurkar; Haiyan Luo; Bruce Cropp; Ricardo Carrion; Melissa de la Garza; Beth-Ann Coller; David Clements; Steven Ogata; Teri Wong; Tim Martyak; Carolyn Weeks-Levy Journal: Clin Vaccine Immunol Date: 2009-07-29
Authors: Stephen C Dreskin; Neal A Halsey; John M Kelso; Robert A Wood; Donna S Hummell; Kathryn M Edwards; Jean-Christoph Caubet; Renata J M Engler; Michael S Gold; Claude Ponvert; Pascal Demoly; Mario Sanchez-Borges; Antonella Muraro; James T Li; Menachem Rottem; Lanny J Rosenwasser Journal: World Allergy Organ J Date: 2016-09-16 Impact factor: 4.084
Authors: Albert To; Liana O Medina; Kenji O Mfuh; Michael M Lieberman; Teri Ann S Wong; Madhuri Namekar; Eileen Nakano; Chih-Yun Lai; Mukesh Kumar; Vivek R Nerurkar; Axel T Lehrer Journal: mSphere Date: 2018-01-10 Impact factor: 4.389
Authors: Yvonne Beck; Richard Fritz; Klaus Orlinger; Stefan Kiermayr; Reinhard Ilk; Daniel Portsmouth; Eva-Maria Pöllabauer; Alexandra Löw-Baselli; Annett Hessel; Doris Kölch; M Keith Howard; P Noel Barrett; Thomas R Kreil Journal: J Virol Date: 2015-12-09 Impact factor: 5.103